Show simple item record

dc.contributor.authorBatur, Şebnem
dc.contributor.authorDülger, Onur
dc.contributor.authorDurak, Şermin
dc.contributor.authorYumuk, Perran Fulden
dc.contributor.authorÇağlar, Hale Başak
dc.contributor.authorBozkurtlar, Emine
dc.contributor.authorBozkurt, Süheyla
dc.contributor.authorTaştekin, Ebru
dc.contributor.authorÇiçin, İrfan
dc.contributor.authorAhiskalı, Rengin
dc.contributor.authorÇakır, Aslı
dc.contributor.authorÖz, Büge
dc.date.accessioned2020-03-23T06:16:12Z
dc.date.available2020-03-23T06:16:12Z
dc.date.issued2020en_US
dc.identifier.citationBatur, Ş., Dülger, O., Durak, Ş., Yumuk, P. F., Çağlar, H. B., Bozkurtlar, E. ... Öz, B. (2020). Concordance of PD-L1 expression and CD8+ TIL intensity between NSCLC and synchronous brain metastases. Bosnian Journal of Basic Medical Sciences, 20(3), 329-335. https://doi.org/10.17305/bjbms.2019.4474en_US
dc.identifier.urihttps://doi.org/10.17305/bjbms.2019.4474
dc.identifier.urihttps://hdl.handle.net/20.500.12511/5056
dc.description.abstractProgrammed death-ligand 1 (PD-L1) is suggested to be a predictive biomarker in non-small-cell lung carcinoma (NSCLC). However, the differential expression of PD-L1 in primary lung tumor vs. synchronous metastases, especially brain metastasis (BM), remains unclear. This study assessed the concordance of PD-L1 expression on tumor cells and tumor-infiltrating lymphocytes (TILs) and CD8+ TIL intensity between primary lung tumors and synchronous BMs from 24 NSCLC patients. PD-L1, CD3, and CD8 positivity was determined by immunohistochemistry (IHC). PD-L1 scoring was based on the proportion of tumor cells with membranous expression of PD-L1 and the cutoff values <1%, 1–49%, and ≥50%. CD3 and CD8 positivity in TILs was evaluated semi-quantitatively and the proportion of CD3+/CD8+ TILs was determined. PD-L1 expression on tumor cells and TILs was evaluated in relation to CD3+/CD8+ TIL proportions and the intensity of CD8+ TILs between the paired primary lung and BM tissues. In the primary lung tumors, PD-L1 positivity was observed in 25%, 37.5%, and 37.5% cases for the cutoff values <1%, 1–49%, and ≥50%, respectively. PD-L1 expression on tumor cells was strongly correlated between the paired primary lung and BM tissues, in all cutoff groups. However, PD-L1 expression on TILs and the proportion of CD3+/CD8+ TILs were not strongly correlated in all three groups between the paired primary lung tumors and BMs. The intensity of CD8+ TILs was concordant in only 54.16% of the paired primary lung tumors and BMs. This study showed a high concordance of PD-L1 expression in neoplastic cells between primary NSCLC and synchronous BMs.en_US
dc.language.isoengen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rightsAttribution 4.0 International*
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/*
dc.subjectProgrammed Death-Ligand 1en_US
dc.subjectNon-Small-Cell Lung Canceren_US
dc.subjectNSCLCen_US
dc.subjectTumor Immunologyen_US
dc.subjectPD-L1en_US
dc.subjectBrain Metastasisen_US
dc.subjectCD8 Lymphocytesen_US
dc.subjectTumor Infiltrating Lymphocytesen_US
dc.subjectTILsen_US
dc.titleConcordance of PD-L1 expression and CD8+ TIL intensity between NSCLC and synchronous brain metastasesen_US
dc.typearticleen_US
dc.relation.ispartofBosnian Journal of Basic Medical Sciencesen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Radyasyon Onkolojisi Ana Bilim Dalıen_US
dc.departmentİstanbul Medipol Üniversitesi, Uluslararası Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalıen_US
dc.authorid0000-0003-0128-6947en_US
dc.identifier.volume20en_US
dc.identifier.issue3en_US
dc.identifier.startpage329en_US
dc.identifier.endpage335en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.doi10.17305/bjbms.2019.4474en_US
dc.identifier.wosqualityQ3en_US
dc.identifier.scopusqualityQ2en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/openAccess
Except where otherwise noted, this item's license is described as info:eu-repo/semantics/openAccess